The MYG1 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population featuring targeted disruption of the MYG1 gene in the HAP1 cell line. This genetically diverse pool of knockout cells enables robust loss-of-function studies without the bias introduced by single-cell cloning. By leveraging the haploid nature of HAP1, the population provides a reliable platform for investigating MYG1 deficiency in mitochondrial biology and disease.
HAP1 is a near-haploid human cell line established from the chronic myeloid leukemia cell line KBM-7. It is an adherent, male line carrying a single chromosome copy for most loci, which simplifies genetic knockout construction and minimizes the risk of heterozygous compensation. Thanks to its haploid nature, HAP1 is a mainstay in functional genomics, enabling high-efficiency CRISPR screens, drug-target validation, and phenotypic profiling.
MYG1 encodes a mitochondrial exonuclease thought to participate in the processing and turnover of mitochondrial RNA. It is predicted to interact functionally with established mitochondrial exoribonucleases PNPase (PNPT1) and SUV3 (SUPV3L1), which are key components of the organellar RNA decay machinery. Loss of MYG1 could perturb the degradation of specific RNA substrates, leading to accumulation of aberrant transcripts and downstream effects on mitochondrial translation and respiratory complex assembly. Although direct regulatory factors remain unknown, the association with PNPase and SUV3 places MYG1 within the essential mitochondrial RNA surveillance network.
The haploid genetic background of HAP1 cells ensures that MYG1 knockout phenotypes are unambiguous, as there is no second allele to mask the effect. This makes the model particularly valuable for investigating the gene’s role in neurodevelopmental pathology, given that MYG1 mutations have been associated with intellectual disability and microcephaly. The polyclonal knockout population reflects the full spectrum of gene inactivation events, providing a robust system to link mitochondrial RNA dysregulation to disease phenotypes.
These MYG1 polyclonal knockout cells are suitable for a broad range of assays, including western blot to verify protein absence, RT?qPCR and RNA?seq for transcriptome analysis, and mitochondrial respiration measurements to assess bioenergetic function. They can be employed in immunofluorescence studies to examine mitochondrial morphology and the localization of related exoribonucleases. The cells are ideal for functional genomics screens, drug discovery efforts aimed at mitochondrial RNA processing enzymes, and disease modeling of neurodevelopmental conditions. The polyclonal nature reduces clonal selection artifacts. For further assistance, contact Ascent Research.
